Walleye Trading
DNLI icon

Walleye Trading’s Denali Therapeutics DNLI Stock Holding History

Walleye Trading’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-226,753
Closed -$5.22M – 4794
2023
Q1 		$5.22M Buy
+226,753
New +$6.24M 0.01% 1012
2021
Q2 		– Sell
-835
Closed -$48K – 5228
2021
Q1 		$48K Sell
835
-2,066
-71% -$138K ﹤0.01% 4339
2020
Q4 		$243K Buy
+2,901
New +$175K ﹤0.01% 3353

Other funds holding DNLI

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $53.5M AUM 80.67% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.54B AUM 86.39% 1-Year Est. Return

Walleye Trading's DNLI Position: Q2 2023 in Review

Walleye Trading sold out of Denali Therapeutics (DNLI) in Q2 2023, closing a stake of 226,753 shares — an estimated $5.22M sold.

Walleye Trading first reported a position in DNLI in Q4 2020 and held it in 3 quarters. The position peaked at $5.22M in Q1 2023. 203 funds tracked by Wall St. Rank hold DNLI as of Q2 2023.

  • Walleye Trading reported no remaining Denali Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Walleye Trading sold 226,753 Denali Therapeutics shares in Q2 2023, an estimated $5.22M.
  • Walleye Trading first reported a position in Denali Therapeutics in Q4 2020 and held it in 3 quarters.
  • Walleye Trading's Denali Therapeutics position peaked at $5.22M in Q1 2023.
  • 203 funds tracked by Wall St. Rank held Denali Therapeutics as of Q2 2023.

Based on Walleye Trading's 13F filing for Q2 2023, filed 14 Aug 2023.